Zhejiang Hisoar Pharmaceutical Co Ltd Cash Flow Reinvestment Rate
Zhejiang Hisoar Pharmaceutical Co Ltd cash flow reinvestment rate. Zhejiang Hisoar Pharmaceutical Co Ltd (002099) has a Cash Flow Reinvestment Rate of 1.07x as of September 2025, reinvesting CN¥16.52 Million (capex CN¥16.52 Million ) from operating cash flow of CN¥15.48 Million. See financial flexibility index of Zhejiang Hisoar Pharmaceutical Co Ltd to measure the company's free cash flow as a share of total liabilities.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of Zhejiang Hisoar Pharmaceutical Co Ltd (2004–2024)
Cash flow reinvestment rate of Zhejiang Hisoar Pharmaceutical Co Ltd from 2004 to 2024. Historical reinvestment intensity for Zhejiang Hisoar Pharmaceutical Co Ltd across 21 annual periods. Explore how well can Zhejiang Hisoar Pharmaceutical Co Ltd service its debt to assess how comfortably operating cash covers total debt obligations.
Zhejiang Hisoar Pharmaceutical Co Ltd Cash Flow Reinvestment Rate by Year (2004–2024)
Zhejiang Hisoar Pharmaceutical Co Ltd cash flow reinvestment rate by year from 2004 to 2024. Year-by-year capital reinvestment analysis for Zhejiang Hisoar Pharmaceutical Co Ltd. For the full cash flow conversion analysis, see how efficiently does Zhejiang Hisoar Pharmaceutical Co Ltd generate cash.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.84x | CN¥146.11 Million | CN¥174.83 Million | CN¥122.11 Million | ▲ +10.7% |
| 2023 | 0.76x | CN¥181.63 Million | CN¥240.54 Million | CN¥153.08 Million | ▼ -86.3% |
| 2022 | 5.50x | CN¥638.56 Million | CN¥116.09 Million | CN¥179.42 Million | ▲ +16.4% |
| 2021 | 4.72x | CN¥483.56 Million | CN¥102.36 Million | CN¥229.56 Million | ▲ +3294.3% |
| 2020 | 0.14x | CN¥74.30 Million | CN¥533.87 Million | CN¥74.18 Million | ▼ -91.8% |
| 2019 | 1.70x | CN¥1.04 Billion | CN¥612.40 Million | CN¥160.64 Million | ▲ +21.6% |
| 2018 | 1.40x | CN¥1.11 Billion | CN¥791.45 Million | CN¥255.78 Million | ▼ -38.4% |
| 2017 | 2.27x | CN¥232.73 Million | CN¥102.68 Million | CN¥148.99 Million | ▲ +385.4% |
| 2016 | 0.47x | CN¥293.90 Million | CN¥629.42 Million | CN¥124.31 Million | ▼ -53.7% |
| 2015 | 1.01x | CN¥465.94 Million | CN¥462.16 Million | CN¥296.36 Million | ▲ +14.2% |
| 2014 | 0.88x | CN¥169.06 Million | CN¥191.56 Million | CN¥169.06 Million | ▼ -80.9% |
| 2013 | 4.63x | CN¥281.79 Million | CN¥60.85 Million | CN¥281.79 Million | ▲ +96.1% |
| 2012 | 2.36x | CN¥426.79 Million | CN¥180.73 Million | CN¥426.79 Million | ▲ +0.5% |
| 2011 | 2.35x | CN¥217.52 Million | CN¥92.62 Million | CN¥217.52 Million | ▲ +190.0% |
| 2010 | 0.81x | CN¥146.51 Million | CN¥180.88 Million | CN¥146.51 Million | ▲ +48.7% |
| 2009 | 0.54x | CN¥53.60 Million | CN¥98.38 Million | CN¥53.60 Million | ▼ -81.6% |
| 2008 | 2.95x | CN¥90.40 Million | CN¥30.61 Million | CN¥90.40 Million | ▲ +34.1% |
| 2007 | 2.20x | CN¥112.61 Million | CN¥51.14 Million | CN¥112.61 Million | ▲ +32.8% |
| 2006 | 1.66x | CN¥102.59 Million | CN¥61.88 Million | CN¥102.59 Million | ▼ -18.9% |
| 2005 | 2.04x | CN¥73.74 Million | CN¥36.07 Million | CN¥73.74 Million | ▲ +103.6% |
| 2004 | 1.00x | CN¥42.54 Million | CN¥42.36 Million | CN¥42.54 Million | — |